<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152707</url>
  </required_header>
  <id_info>
    <org_study_id>LUM-ABU-SPLENDOR X-2019-01</org_study_id>
    <nct_id>NCT04152707</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of Splendor X for Hair Removal</brief_title>
  <official_title>Clinical Evaluation of Splendor X for Hair Removal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumenis Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumenis Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least 40 healthy male or female subjects that wish to remove their hair will be enrolled&#xD;
      to this study.&#xD;
&#xD;
      Each subject will receive five treatments at 6-8 weeks intervals. Subjects will return for&#xD;
      follow-up visits at 3, 6, 9, and 12 months after the last treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 8, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hair reduction</measure>
    <time_frame>3 months follow up</time_frame>
    <description>change in number of hairs at 3 months following the last treatment as compared to baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hair Remval</condition>
  <arm_group>
    <arm_group_label>Splendor X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Splendor X</intervention_name>
    <description>The Splendor X has two wavelengths in one system: Nd:YAG (1064nm) and Alexandrite (755nm).</description>
    <arm_group_label>Splendor X</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand and provide written Informed Consent;&#xD;
&#xD;
          2. All skin types: I-VI&#xD;
&#xD;
          3. Male or female&#xD;
&#xD;
          4. Age - 18-50 years of age&#xD;
&#xD;
          5. Having one suitable treatment areas (legs, back, Chest or abdomen) with dark brown or&#xD;
             black hair appropriate for hair removal;&#xD;
&#xD;
          6. Interested in laser hair removal treatment for permanent hair reduction in the&#xD;
             suitable area&#xD;
&#xD;
          7. Able and willing to comply with the treatment/follow-up schedule and requirements;&#xD;
&#xD;
          8. Women of child-bearing age are required to be using a reliable method of birth control&#xD;
             at least 3 months prior to enrollment and throughout the course of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, expectation of pregnancy, postpartum or nursing (&lt;6 months);&#xD;
&#xD;
          2. Participation in another clinical study&#xD;
&#xD;
          3. Active infections in the treated area;&#xD;
&#xD;
          4. Dysplastic nevi in the treatment area;&#xD;
&#xD;
          5. Tattoos in the treatment area;&#xD;
&#xD;
          6. Current cancer, history of skin cancer or pre-cancerous lesions at the treatment&#xD;
             areas;&#xD;
&#xD;
          7. History of keloid scars anywhere on the body or scar formation in the treatment area ;&#xD;
             or at risk of Keloid scars&#xD;
&#xD;
          8. Active cold sores, open lacerations or abrasions in the treated area;&#xD;
&#xD;
          9. Herpes simplex in the treatment area&#xD;
&#xD;
         10. Prior skin treatment with laser or other devices on the same treated areas prior to&#xD;
             study enrollment or during the course of the study&#xD;
&#xD;
         11. Significant concurrent skin conditions or any inflammatory skin conditions;&#xD;
&#xD;
         12. Chronic or cutaneous viral, fungal, or bacterial diseases;&#xD;
&#xD;
         13. Intense tan, Deep suntan, recent suntan within 2 weeks, sunburn or artificially tanned&#xD;
             skin;&#xD;
&#xD;
         14. Use of medications, herbal supplements, perfumes or cosmetics that may affect&#xD;
             sensitivity to light or change skin metabolism&#xD;
&#xD;
         15. Skin lesions&#xD;
&#xD;
         16. Bleeding coagulopathies or use of anticoagulants&#xD;
&#xD;
         17. Hormonal disorders that may affect hair growth;&#xD;
&#xD;
         18. Immunosuppressive diseases, including AIDS and HIV infection, or use of&#xD;
             immunosuppressive medications; or other auto-immune dsorders.&#xD;
&#xD;
         19. Livedo reticularis;&#xD;
&#xD;
         20. Uncontrolled systemic diseases such as diabetes;&#xD;
&#xD;
         21. Use of Accutaneâ„¢ (Isotretinoin) within the past 6 month;&#xD;
&#xD;
         22. Erythema ab igne, when identified treatments should be discontinued;&#xD;
&#xD;
         23. Photosensitivity disorder that can be exacerbated by laser or intense light (such as&#xD;
             Epilepsy).&#xD;
&#xD;
         24. Poor wound healing;&#xD;
&#xD;
         25. Unable or unlikely to refrain from artificial tanning, including the use of tanning&#xD;
             booths, prior (at least 6 week) and during the course of the evaluation;&#xD;
&#xD;
         26. Previous skin procedures on requested treatment area (botox, fillers , peels , lasers&#xD;
             etc. )&#xD;
&#xD;
         27. Mechanical or chemical hair removal in the treated area within 6 weeks before the&#xD;
             laser treatment&#xD;
&#xD;
         28. Subjects who do not desire permanent hair reduction in the areas to be treated&#xD;
&#xD;
         29. As per the Investigator's discretion, any physical or mental condition which might&#xD;
             make it unsafe for the subject to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Rohrer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>SkinCare Physicians</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Chapas, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Union Square Laser Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SkinCare Physicians</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Square Laser Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 3, 2019</study_first_submitted>
  <study_first_submitted_qc>November 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

